公开(公告)号：WO2021122925A1

公开(公告)日：2021-06-24

申请号：PCT/EP2020/086680

申请日：2020-12-17

Applicant: BAXTER INTERNATIONAL INC. ,  BAXTER HEALTHCARE SA

Inventor： DUPONT, Caroline ,  BOUREZG, Zouaoui

IPC: A61K9/00 ,  A61K9/08 ,  A61K9/0019 ,  A61K9/0053

Abstract: The invention relates to a medical product for preventing or correcting selenium deficiency in a patient comprising a solution provided in a flexible container characterized in that the solution comprises at least one of a selenate salt and/or a seleno-amino acid, such as selenomethionine or selenocysteine.

公开(公告)号：WO2022251106A1

公开(公告)日：2022-12-01

申请号：PCT/US2022/030517

申请日：2022-05-23

Applicant: BAXTER INTERNATIONAL INC. ,  BAXTER HEALTHCARE SA

Inventor： BOUREZG, Zouaoui ,  DUPONT, Caroline Roselyne ,  DESBROSSES, Freddy ,  COUTHOUIS, Aurélie ,  BROSSARD, Gabriel ,  PADULA, Pierpaolo ,  TROUILLY, Jean-Luc

IPC: A23L33/00 ,  A23L33/115 ,  A23L33/125 ,  A23L33/15 ,  A23L33/155 ,  A23L33/16 ,  A23L33/175 ,  B65D81/32 ,  A61J1/20

Abstract: The present disclosure relates to a terminally heat-sterilized ready-to-use parenteral nutrition formulation comprising all macronutrients and micronutrients required to meet the clinical guidelines for parenteral nutrition, wherein all said micronutrients and macronutrients are provided in one multi-chamber bag (MCB). The disclosure is also directed to a parenteral nutrition formulation comprising all such macronutrients and micronutrients. More specifically, the present disclosure is directed to a MCB comprising at least five chambers containing a carbohydrate formulation in a first chamber, an amino acid formulation in a second chamber, a lipid formulation in a third chamber, a fourth chamber comprising a vitamin formulation and a fifth chamber comprising a trace element formulation, wherein the carbohydrate formulation, amino acid formulation and/or the lipid formulation may also contain certain vitamins and certain trace elements that can be stably accommodated therein.

公开(公告)号：WO2021122923A1

公开(公告)日：2021-06-24

申请号：PCT/EP2020/086678

申请日：2020-12-17

Applicant: BAXTER INTERNATIONAL INC. ,  BAXTER HEALTHCARE SA

Inventor： DUPONT, Caroline ,  BOUREZG, Zouaoui

IPC: A61K33/04 ,  A61P3/02

Abstract: The invention relates to a medical product for preventing or correcting selenium deficiency in a patient comprising a solution provided in a flexible container comprising at least one selenium compound in the form of Se (IV), which is preferably selected from the group consisting of sodium selenite, selenous acid and selenium dioxide, characterized in that the solution comprises dissolved oxygen (DO), preferably 0.5 ppm to 8 ppm DO.

公开(公告)号：WO2022251810A1

公开(公告)日：2022-12-01

申请号：PCT/US2022/072505

申请日：2022-05-23

Applicant: BAXTER INTERNATIONAL INC. ,  BAXTER HEALTHCARE SA

Inventor： DESBROSSES, Freddy ,  PADULA, Pierpaolo ,  DUPONT, Caroline Roselyne ,  DEMULIER, Marin Anh-Thuan ,  BOUREZG, Zouaoui

IPC: A61K9/00 ,  A61K47/02

Abstract: The invention relates to a flexible container/multi-chamber container with selective dissolved gas content for stabilizing at least one compound of a medical product having a selective gas requirement for remaining stable, comprising a solution comprising the at least one compound and a fil material from which the container is made that provides for high gas-barrier for the said gas. The at least one compound may be selenium in the form of Se(IV) and is preferably selected from the group consisting of sodium selenite, selenous acid and selenium dioxide. The selective gas may be oxygen, and the headspace of the oxygen maintains the solution to comprise dissolved oxygen (DO) at a level of 0.5 ppm to 8 ppm.

公开(公告)号：WO2022251177A2

公开(公告)日：2022-12-01

申请号：PCT/US2022/030674

申请日：2022-05-24

Applicant: BAXTER INTERNATIONAL INC. ,  BAXTER HEALTHCARE SA

Inventor： BOUREZG, Zouaoui ,  POUSSET, Cyrille

IPC: A61K31/661 ,  A61K9/08 ,  A61P3/02 ,  A61P3/12 ,  C07F9/11 ,  A61K9/0029 ,  A61L2/0023 ,  C07F9/091

Abstract: The present disclosure relates to a pharmaceutical composition for providing phosphorus to an adult or pediatric patient, wherein the composition is an aqueous solution of sodium glycerophosphate which by virtue of an improved process for producing the active pharmaceutical ingredient and the pharmaceutical composition is characterized by a low amount of free phosphate, a low amount of SGP-related substances and by a low amount of aluminum. The pharmaceutical composition is used in clinical nutrition, preferably in the preparation of nutritional formulations by compounding. The compositions can further be used for preventing or correcting phosphorus deficiency (hyperphosphatemia) in said adult or pediatric patients.

公开(公告)号：WO2022063963A1

公开(公告)日：2022-03-31

申请号：PCT/EP2021/076321

申请日：2021-09-24

Applicant: BAXTER INTERNATIONAL INC. ,  BAXTER HEALTHCARE SA

Inventor： DUPONT, Caroline ,  BOUREZG, Zouaoui ,  COUTHOUIS, Aurélie

IPC: A61K9/00 ,  A61K31/198 ,  A61K31/4415 ,  A61K31/455 ,  A61K31/525 ,  A61K31/714 ,  A61P43/00 ,  A61K9/08 ,  A61K9/10 ,  A61K47/44

Abstract: The invention relates to a terminally heat-sterilized multi-chamber container for parenteral nutrition, comprising a first chamber containing a macronutrient formulation and a second chamber comprising a vitamin B12 formulation, wherein the vitamin B12 formulation (a) is essentially free from glucose, amino acids, vitamin B1, ascorbyl palmitate and/or vitamin C; and (b) stably comprises vitamin B12 for at least 6 months at a temperature of from 1°C to 40°C and/or for at least 24 months at a temperature of 25°C.

公开(公告)号：WO2022063956A1

公开(公告)日：2022-03-31

申请号：PCT/EP2021/076313

申请日：2021-09-24

Applicant: BAXTER INTERNATIONAL INC. ,  BAXTER HEALTHCARE SA

Inventor： BOUREZG, Zouaoui ,  DUPONT, Caroline ,  BROSSARD, Gabriel ,  TROUILLY, Jean-Luc ,  COUTHOUIS, Aurélie

IPC: A61K9/00 ,  A61K47/14 ,  A61K47/44 ,  A61P3/02

Abstract: The invention relates to a medical product for preventing or correcting vitamin A deficiency in a patient comprising a lipid emulsion in a flexible container, the lipid emulsion comprising (a) vitamin A in the lipid phase of the lipid emulsion, (b) optionally additionally vitamin D, vitamin E and/or vitamin K in the lipid phase of the lipid emulsion, and (c) no more than 1.5 ppm dissolved oxygen (DO), (d) wherein the pH of the lipid emulsion is from 5 to 9.